Abstract
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, EC 1.2.1.12) is a glycolytic enzyme catalyzing the formation of 1,3-diphosphoglycerate from glyceraldehyde-3-phosphate and inorganic phosphate. In cooperation with E3 ubiquitin-kinase Siah1, GAPDH directly participates in the apoptotic death of neurons in Parkinson’s disease. Potential GAPDH inhibitors were screened in silico, and three compounds with high affinity to the NAD-binding site and theoretically capable of forming a disulfide bond with amino acid residue Cys149 were found among cysteine and glutathione derivatives. The inhibitory effect of these compounds was tested on GAPDH from rabbit muscles using isothermal calorimetry and kinetic methods. As a result of experimental screening, we selected two compounds that inhibit GAPDH by forming disulfide bonds with the Cys149 residue in the enzyme active site. Since Cys149 is the key residue not only for the catalyzed reaction, but also for interaction with Siah1, the compounds can be assumed to inhibit the formation of the proapoptotic complex GAPDH-Siah1 and therefore have potential effect against Parkinson’s disease.
Similar content being viewed by others
Abbreviations
- GAPDH:
-
glyceraldehyde-3-phosphate dehydrogenase
References
Buehner, M., Ford, G. C., Olsen, K. W., Moras, D., and Rossman, M. G. (1974) J. Mol. Biol., 90, 25–49.
Mohr, S., Stamler, J. S., and Brune, B. (1994) FEBS Lett., 348, 223–227.
Schmalhausen, E. V., Pleten’, A. P., and Muronetz, V. I. (2003) Biochem. Biophys. Res. Commun., 308, 492–496.
Polgar, L. (1975) Eur. J. Biochem., 51, 63–71.
Stallcup, W. B., and Koshland, D. E., Jr. (1973) J. Mol. Biol., 80, 41–62.
Hyslop, P. A., Hinshaw, D. B., Halsey, W. A., Schraufstatter, I. U., Sauerheber, R. D., Spragg, R. G., Jackson, J. H., and Cochrane, C. G. (1988) J. Biol. Chem., 263, 1665–1675.
Sirover, M. A. (1999) Biochim. Biophys. Acta, 1432, 159–184.
Mazzola, J. L., and Sirover, M. A. (2001) J. Neurochem., 76, 442–449.
Ishitani, R., Tanaka, M., Sunaga, K., Katsube, N., and Chuang, D. M. (1998) Mol. Pharmacol., 53, 701–707.
Arutyunova, E. I., Danshina, P. V., Domnina, L. V., Pleten, A. P., and Muronetz, V. I. (2003) Biochem. Biophys. Res. Commun., 307, 547–552.
Andringa, G., van Oosten, R. V., Unger, W., Hafmans, T. G., Veening, J., Stoof, J. C., and Cools, A. R. (2000) Eur. J. Neurosci., 12, 3033–3043.
Waldmeier, P. C., Boulton, A. A., Cools, A. R., Kato, A. C., and Tatton, W. G. (2000) J. Neural Transm. Suppl., 60, 197–214.
Jenkins, J. L., and Tanner, J. J. (2006) Acta Crystallogr. D. Biol. Crystallogr., 62(Pt. 3), 290–301.
Chuang, D., Hough, C., and Senatorov, V. V. (2005) Annu. Rev. Pharmacol. Toxicol., 45, 269–290.
Scopes, R. K., and Stoter, A. (1982) Meth. Enzymol., 90, 479–490.
Stroganov, O. V., Novikov, F. N., Stroylov, V. S., Kulkov, V., and Chilov, G. G. (2008) J. Chem. Inf. Model., 48, 2371–2385.
Guranda, D. T., Kudryavtsev, P. A., Khimiuk, A. Y., and Švedas, V. K. (2005) J. Chromatogr. A, 1095, 89–93.
Vijlder, J. J. M., Boers, W., and Slater, E. C. (1969) Biochim. Biophys. Acta, 191, 214–220.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in Russian in Biokhimiya, 2010, Vol. 75, No. 12, pp. 1662–1669.
Originally published in Biochemistry (Moscow) On-Line Papers in Press, as Manuscript BM10-165, October 10, 2010.
Rights and permissions
About this article
Cite this article
Chernorizov, K.A., Elkina, J.L., Semenyuk, P.I. et al. Novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase: Covalent modification of NAD-binding site by aromatic thiols. Biochemistry Moscow 75, 1444–1449 (2010). https://doi.org/10.1134/S0006297910120047
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0006297910120047